RJFSA
AQST icon

Raymond James Financial Services Advisors’s Aquestive Therapeutics AQST Stock Holding History

Raymond James Financial Services Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$79.8K Buy
16,032
+532
+3% +$2.07K ﹤0.01% 3322
2024
Q2 		$40.3K Sell
15,500
-1,000
-6% -$3.34K ﹤0.01% 3316
2024
Q1 		$70.3K Buy
+16,500
New +$54.9K ﹤0.01% 3264

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Raymond James Financial Services Advisors's AQST Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Aquestive Therapeutics (AQST) stake by 3.4% in Q3 2024, buying an estimated $2.07K and bringing the position to 16,032 shares worth $79.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3322.

Raymond James Financial Services Advisors first reported a position in AQST in Q1 2024 and has held it in 3 quarters since. 117 funds tracked by Wall St. Rank hold AQST as of Q3 2024.

  • Raymond James Financial Services Advisors held 16,032 shares of Aquestive Therapeutics worth $79.8K as of Q3 2024.
  • Raymond James Financial Services Advisors bought 532 Aquestive Therapeutics shares in Q3 2024, an estimated $2.07K.
  • Aquestive Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3322 holding.
  • Raymond James Financial Services Advisors first reported a position in Aquestive Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 117 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.